bioMérieux: Approval of VITEK MS in the US

NEUTRAL, Fair Value EUR66 (-14%)

News published on August Thursday 22, 2013
Share on

bioMérieux announced yesterday night that the FDA has granted approval to VITEK MS, the first clinical mass spectrometry MALDI-TOF-based system available in the US. There is no doubt that this is a significant achievement for the company as the system will dramatically reduce the time to detect disease-causing microorganisms. We estimate that the price of VITEK MS is around USD200k. bioMérieux acquired a licence from Shimadzu related to MALDI-TOF technology in 2010 which should result in payments to the Japanese company. A second mass spec instrument from Burker and Becton Dickinson is expected to reach the market later in the year. As a reminder, bioMérieux and BD are #1 and #2 in terms of market shares in microbiology (50% of bioMérieux sales). We continue to be Neutral on the stock as solid fundamentals continue to be offset by margin pressure and valuation (17.4x 2014e for an high single-digit EPS expansion).

Full report available to subscribers
Please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities